In the rapidly evolving landscape of cancer therapy, one class of drugs is making waves for its game-changing impact: CDK4/6 inhibitors. These revolutionary agents are rewriting the narrative for treating cancers driven by uncontrolled cell division, particularly hormone receptor-positive, HER2-negative breast cancers. By targeting the critical regulators of the cell cycle, CDK4/6 inhibitors strike at the very heart of cancer’s relentless growth, offering new hope to patients and clinicians alike. With promising data, innovative combinations, and expanding indications, CDK4/6 inhibitors are spearheading a new oncology era—where science meets precision for truly transf...
